Global Pulmonary Drug Delivery Devices Market Overview And Scope:
Global Pulmonary Drug Delivery Devices Market Size was estimated at USD 2959.14 million in 2022 and is projected to reach USD 3796.83 million by 2028, exhibiting a CAGR of 4.24% during the forecast period.
The Global Pulmonary Drug Delivery Devices Market Report 2023 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Pulmonary Drug Delivery Devices utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2023 and 2030. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
Top Key Players Mentioned Are: Boehringer Ingelheim GmbH, Novartis AG, GlaxoSmithKline, AstraZeneca, Teva Pharmaceutical Industries, Merck, MannKind, Bristol-Myers Squibb, Mylan N.V, Omron Corp, F. Hoffmann-La Roche, 3M Healthcare, Sunovion Pharmaceuticals, Koninklijke Philips N.V, Gerresheimer AG, Bespak, AptarGroup, SHL Group, Nypro Healthcare, Hovione, Chiesi Farmaceutici S.P.A
Global Pulmonary Drug Delivery Devices Market Segmentation
By Type, Pulmonary Drug Delivery Devices market has been segmented into:Dry Powder Inhaler
Metered Dose Inhaler
Nebulizer
By Application, Pulmonary Drug Delivery Devices market has been segmented into:
Asthma
COPD
Cystic Fibrosis
Other
Regional Analysis:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Pulmonary Drug Delivery Devices market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Pulmonary Drug Delivery Devices market.
Top Key Players Covered in Pulmonary Drug Delivery Devices market are:
Boehringer Ingelheim GmbH
Novartis AG
GlaxoSmithKline
AstraZeneca
Teva Pharmaceutical Industries
Merck
MannKind
Bristol-Myers Squibb
Mylan N.V
Omron Corp
F. Hoffmann-La Roche
3M Healthcare
Sunovion Pharmaceuticals
Koninklijke Philips N.V
Gerresheimer AG
Bespak
AptarGroup
SHL Group
Nypro Healthcare
Hovione
Chiesi Farmaceutici S.P.A
Objective to buy this Report:
1. Pulmonary Drug Delivery Devices analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Pulmonary Drug Delivery Devices market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Pulmonary Drug Delivery Devices Market by Type
5.1 Pulmonary Drug Delivery Devices Market Overview Snapshot and Growth Engine
5.2 Pulmonary Drug Delivery Devices Market Overview
5.3 Dry Powder Inhaler
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2016-2030F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Dry Powder Inhaler: Geographic Segmentation
5.4 Metered Dose Inhaler
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2016-2030F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Metered Dose Inhaler: Geographic Segmentation
5.5 Nebulizer
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2016-2030F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Nebulizer: Geographic Segmentation
Chapter 6: Pulmonary Drug Delivery Devices Market by Application
6.1 Pulmonary Drug Delivery Devices Market Overview Snapshot and Growth Engine
6.2 Pulmonary Drug Delivery Devices Market Overview
6.3 Asthma
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2016-2030F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Asthma: Geographic Segmentation
6.4 COPD
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2016-2030F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 COPD: Geographic Segmentation
6.5 Cystic Fibrosis
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2016-2030F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Cystic Fibrosis: Geographic Segmentation
6.6 Other
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size (2016-2030F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Other: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Pulmonary Drug Delivery Devices Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Pulmonary Drug Delivery Devices Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Pulmonary Drug Delivery Devices Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 BOEHRINGER INGELHEIM GMBH
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 NOVARTIS AG
7.4 GLAXOSMITHKLINE
7.5 ASTRAZENECA
7.6 TEVA PHARMACEUTICAL INDUSTRIES
7.7 MERCK
7.8 MANNKIND
7.9 BRISTOL-MYERS SQUIBB
7.10 MYLAN N.V
7.11 OMRON CORP
7.12 F. HOFFMANN-LA ROCHE
7.13 3M HEALTHCARE
7.14 SUNOVION PHARMACEUTICALS
7.15 KONINKLIJKE PHILIPS N.V
7.16 GERRESHEIMER AG
7.17 BESPAK
7.18 APTARGROUP
7.19 SHL GROUP
7.20 NYPRO HEALTHCARE
7.21 HOVIONE
7.22 CHIESI FARMACEUTICI S.P.A
Chapter 8: Global Pulmonary Drug Delivery Devices Market Analysis, Insights and Forecast, 2016-2030
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Dry Powder Inhaler
8.2.2 Metered Dose Inhaler
8.2.3 Nebulizer
8.3 Historic and Forecasted Market Size By Application
8.3.1 Asthma
8.3.2 COPD
8.3.3 Cystic Fibrosis
8.3.4 Other
Chapter 9: North America Pulmonary Drug Delivery Devices Market Analysis, Insights and Forecast, 2016-2030
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Dry Powder Inhaler
9.4.2 Metered Dose Inhaler
9.4.3 Nebulizer
9.5 Historic and Forecasted Market Size By Application
9.5.1 Asthma
9.5.2 COPD
9.5.3 Cystic Fibrosis
9.5.4 Other
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Pulmonary Drug Delivery Devices Market Analysis, Insights and Forecast, 2016-2030
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Dry Powder Inhaler
10.4.2 Metered Dose Inhaler
10.4.3 Nebulizer
10.5 Historic and Forecasted Market Size By Application
10.5.1 Asthma
10.5.2 COPD
10.5.3 Cystic Fibrosis
10.5.4 Other
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Pulmonary Drug Delivery Devices Market Analysis, Insights and Forecast, 2016-2030
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Dry Powder Inhaler
11.4.2 Metered Dose Inhaler
11.4.3 Nebulizer
11.5 Historic and Forecasted Market Size By Application
11.5.1 Asthma
11.5.2 COPD
11.5.3 Cystic Fibrosis
11.5.4 Other
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Pulmonary Drug Delivery Devices Market Analysis, Insights and Forecast, 2016-2030
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Dry Powder Inhaler
12.4.2 Metered Dose Inhaler
12.4.3 Nebulizer
12.5 Historic and Forecasted Market Size By Application
12.5.1 Asthma
12.5.2 COPD
12.5.3 Cystic Fibrosis
12.5.4 Other
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Pulmonary Drug Delivery Devices Market Analysis, Insights and Forecast, 2016-2030
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Dry Powder Inhaler
13.4.2 Metered Dose Inhaler
13.4.3 Nebulizer
13.5 Historic and Forecasted Market Size By Application
13.5.1 Asthma
13.5.2 COPD
13.5.3 Cystic Fibrosis
13.5.4 Other
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Pulmonary Drug Delivery Devices Market Analysis, Insights and Forecast, 2016-2030
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Dry Powder Inhaler
14.4.2 Metered Dose Inhaler
14.4.3 Nebulizer
14.5 Historic and Forecasted Market Size By Application
14.5.1 Asthma
14.5.2 COPD
14.5.3 Cystic Fibrosis
14.5.4 Other
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Pulmonary Drug Delivery Devices Scope:
|
Report Data
|
Pulmonary Drug Delivery Devices Market
|
|
Pulmonary Drug Delivery Devices Market Size in 2022
|
USD 2959.14 million
|
|
Pulmonary Drug Delivery Devices CAGR 2023 - 2030
|
4.24%
|
|
Pulmonary Drug Delivery Devices Base Year
|
2022
|
|
Pulmonary Drug Delivery Devices Forecast Data
|
2023 - 2030
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Boehringer Ingelheim GmbH, Novartis AG, GlaxoSmithKline, AstraZeneca, Teva Pharmaceutical Industries, Merck, MannKind, Bristol-Myers Squibb, Mylan N.V, Omron Corp, F. Hoffmann-La Roche, 3M Healthcare, Sunovion Pharmaceuticals, Koninklijke Philips N.V, Gerresheimer AG, Bespak, AptarGroup, SHL Group, Nypro Healthcare, Hovione, Chiesi Farmaceutici S.P.A.
|
|
Key Segments
|
By Type
Dry Powder Inhaler
Metered Dose Inhaler
Nebulizer
By Applications
Asthma
COPD
Cystic Fibrosis
Other
|
